ArticleCytotherapy2015
Phenotypic and functional characterization of macrophages with therapeutic potential generated from human cirrhotic monocytes in a cohort study.
Article in Cytotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 48 citations in OpenAlex.
- Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial.Nature medicine · 2025Trial
- The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial.Scientific reports · 2024Trial
- Harnessing macrophage signaling pathways and scalable engineering for next-generation immunotherapies.Signal transduction and targeted therapy · 2026Review
- Cell Therapy in Advanced Cirrhosis: From Preclinical Evidence to Clinical Application.Gastro hep advances · 2026Review
- New perspectives in the treatment of liver cirrhosis: targeting macrophage regulatory mechanisms.Journal of translational medicine · 2025Review
- Not the end of the road for macrophage therapy in liver cirrhosis.Nature medicine · 2025Article
- Wharton's Jelly mesenchymal stem cell-derived extracellular vesicles induce liver fibrosis-resolving phenotype in alternatively activated macrophages.Journal of cellular and molecular medicine · 2024Article
- Protozoan-Derived Cytokine-Transgenic Macrophages Reverse Hepatic Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells.Frontiers in immunology · 2024Article
- The Current Proceedings of PSC-Based Liver Fibrosis Therapy.Stem cell reviews and reports · 2023Review
- Cell therapy in end-stage liver disease: replace and remodel.Stem cell research & therapy · 2023Review
- Macrophage cytotherapy on liver cirrhosis.Frontiers in pharmacology · 2023Review
- Deciphering the Molecular Signature of Human Hyalocytes in Relation to Other Innate Immune Cell Populations.Investigative ophthalmology & visual science · 2022Article
- The versatility of macrophage heterogeneity in liver fibrosis.Frontiers in immunology · 2022Review
- In-Depth Molecular Profiling Specifies Human Retinal Microglia Identity.Frontiers in immunology · 2022Article
- Article
- Liver regeneration and inflammation: from fundamental science to clinical applications.Nature reviews. Molecular cell biology · 2021Review
- Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System.Frontiers in medicine · 2021Review
- Alternatively activated macrophages promote resolution of necrosis following acute liver injury.Journal of hepatology · 2020Article
- Transcriptional Profiling Uncovers Human Hyalocytes as a Unique Innate Immune Cell Population.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND
aimsMacrophages have complex roles in the liver. The aim of this study was to compare profiles of human monocyte-derived macrophages between controls and cirrhotic patients, to determine whether chronic inflammation affects precursor number or the phenotype, with the eventual aim to develop a cell therapy for cirrhosis.
methodsInfusion of human macrophages in a murine liver fibrosis model demonstrated a decrease in markers of liver injury (alanine transaminase, bilirubin, aspartate transaminase) and fibrosis (transforming growth factor-β, α-smooth muscle actin, phosphatidylserine receptor) and an increase in markers of liver regeneration (matrix metalloproteinases [MMP]-9, MMP-12 and TNF-related weak inducer of apoptosis). CD14+ monocytes were then isolated from controls. Monocytes were matured into macrophages for 7 days using a Good Manufacturing Practice-compatible technique.
resultsThere was no significant difference between the mean number of CD14+ monocytes isolated from cirrhotic patients (n = 9) and controls (n = 10); 2.8 ± SEM 0.54 × 10(8) and 2.5 ± 0.56 × 10(8), respectively. The mean yield of mature macrophages cultured was also not significantly different between cirrhotic patients and controls (0.9 × 10(8) ± 0.38 × 10(8), with more than 90% viability and 0.65 × 10(8) ± 0.16 × 10(8), respectively. Maturation to macrophages resulted in up-regulation of a number of genes (MMP-9, CCL2, interleukin [IL]-10 and TNF-related weak inducer of apoptosis). A cytokine and chemokine polymerase chain reaction array, comparing the control and cirrhotic macrophages, revealed no statistically significant differences.
conclusionsMacrophages can be differentiated from cirrhotic patients' apheresis-derived CD14 monocytes and develop the same pro-resolution phenotype as control macrophages, indicating their suitability for clinical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.